<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82780">
  <stage>Registered</stage>
  <submitdate>24/04/2008</submitdate>
  <approvaldate>1/05/2008</approvaldate>
  <actrnumber>ACTRN12608000225314</actrnumber>
  <trial_identification>
    <studytitle>Does luteal estradiol supplementation have a role in long agonist cycles?"</studytitle>
    <scientifictitle>In intracytoplasmic sperm injection (ICSI) cases using long gonadotropin releasing hormone (GnRH) agonist protocol, does the use of vaginal etradiol luteal supplementation compared to oral estradiol supplementation or propgesterone alone improve luteal hormonal profile or pregnancy rate?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intramuscular (IM) progesterone 100 mg/day starting on day of ET till 8 weeks of gestation + Vaginal application of estradiol valerate tablets 2mg 3 times/day starting on day of embryo transfer (ET) throughout the whole luteal phase. The complete duration of the study is 25 months.</interventions>
    <comparator>1- IM progesterone 100mg/day alone starting on day of ET till 8 weeks of gestation 2- IM progesterone 100mg/day starting on day of ET till 8 weeks of gestation  + Oral estradiol valerate 2mg 3 times/day  starting on day of ET throughout the whole luteal phase.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical pregnancy by assessing clinical pregnancy rate</outcome>
      <timepoint>Human chorionic gonadotrophin (hCG) testing on day 16 and 18 after ET, Ultrasound 3 weeks after +ve hCG testing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Luteal serum estradiol and progesterone levels by electrochemiluminescence immunoasays</outcome>
      <timepoint>Day of human chorionic gonadotropin (hCG) administration (day 0), +7, +10 and +13</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women undergoing intracytoplasmic sperm injection due to male factor of infertility using pituitary desensitization by GnRH agonist long protocol</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>37</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &gt; 37 years, body mass index (BMI) &lt; 18 or &gt; 29, irregular menstral cycles, women with single ovary, day 3 serum follicle stimulating hormone (FSH) 9.5 milli international units (mIU)/ml or more, basal antral follicle count 6 or less, 5 or less retreived mature follicles, non availability of good quality embryos and failure to obtain a written consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After ensuring eligibility and agreement to participate, participants were sent to the unit pharmacy where each participant was asked to select one sealed envelope only once to determine the group to which she will be assigned. The randomization key was kept with the pharmacy director and was not opened until after statistical analysis</concealment>
    <sequence>Block randomization method</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>12/08/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>270</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Eman Amin Elgindy</primarysponsorname>
    <primarysponsoraddress>Cairo, Rehab city, group 60, building 11, apart 22.</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dahlia Osman El-Haieg</sponsorname>
      <sponsoraddress>Cairo, Maadi, 104 street, no 110</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eman Amin Elgindy</name>
      <address>Cairo, Rehab city, group 60, building 11, apart 22</address>
      <phone>020226922453</phone>
      <fax>020552321677</fax>
      <email>eman_elgindy@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dahlia Osman El-Haieg</name>
      <address>Cairo, Maadi, 104 street, no 110</address>
      <phone>020225263936</phone>
      <fax />
      <email>drdalia65@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Magdy I Mostafa</name>
      <address>Cairo, 300 ElGiza square</address>
      <phone>020237756111</phone>
      <fax>020237756111</fax>
      <email>imagdy@link.net</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>